| Literature DB >> 25788941 |
Renping Huang1, Bing Liu1, Hua Chen2, Xuewei Bai2, Rui Kong2, Gang Wang2, Yongwei Wang2, Bei Sun2, Yinghui Guan1.
Abstract
The study aimed to uncover the risk factors for the new defined pancreatic fistula (PF) and clinical related PF (CR-PF) after pancreaticoduodenectomy (PD) surgery and to evaluate the medico-economic effect of patients. A total of 412 patients were classified into two groups according to different criteria, PF and NOPF according to PF occurrence: CR-PF (grades B and C) and NOCR-PF (grade A) based on PF severity. A total of 28 factors were evaluated by univariate and multivariate logistic regression test. Hospital charges and stays of these patients were assessed. The results showed that more hospital stages and charges are needed for patients in PF and CR-PF groups than in NOPF and NOCR-PF groups (P < 0.05). The excessive drinking, soft remnant pancreas, preoperative albumin, and intraoperative blood transfusion are risk factors affecting both PF and CR-PF incidence. More professional surgeons can effectively reduce the PF and CR-PF incidence. Patients with PF and CR-PF need more hospital costs and stages than that in NOPF and NOCR-PF groups. It is critical that surgeons know the risk factors related to PF and CR-PF so as to take corresponding therapeutic regimens for each patient.Entities:
Year: 2015 PMID: 25788941 PMCID: PMC4350616 DOI: 10.1155/2015/917689
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Demographic characteristics description.
| Variants | PF | NOPF | Total |
| CR-PF | NOCR-PF | Total |
|
|---|---|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
| Gender | 0.597 (0.440) | 0.515 (0.473) | ||||||
| Male | 83 (65.9) | 177 (61.9) | 260 (63.1) | 44 (59.5) | 216 (63.9) | 260 (63.1) | ||
| Female | 43 (34.1) | 109 (38.1) | 152 (36.9) | 30 (40.5) | 122 (36.1) | 152 (36.9) | ||
| Age (year) | 0.077 (0.782) | 0.619 (0.431) | ||||||
| <70 | 113 (89.7) | 259 (90.6) | 372 (90.3) | 65 (87.8) | 307 (90.8) | 372 (90.3) | ||
| ≥70 | 13 (10.3) | 27 (9.4) | 40 (9.7) | 9 (12.2) | 31 (9.2) | 40 (9.7) | ||
| BMI | 1.951 (0.377) | 0.328 (0.849) | ||||||
| <18.5 | 14 (11.1) | 41 (14.3) | 55 (13.3) | 9 (12.2) | 46 (13.6) | 55 (13.3) | ||
| 18.5–25 | 90 (71.4) | 208 (72.7) | 298 (72.3) | 53 (71.6) | 245 (72.5) | 298 (72.3) | ||
| ≥25 | 22 (17.5) | 37 (12.9) | 59 (14.3) | 12 (16.2) | 47 (13.9) | 59 (14.3) |
PF: patients undergoing pancreatic fistula after pancreaticoduodenectomy (PD); NOPF: PD patients without PF occur; CR-PF: PF patients diagnosed as grade B fistulas and grade C fistulas; NOCR-PF: non-PF patients and grade A PF patients; BMI: body mass index.
Hospital charges and hospital stays.
| NOPF | PF | NOCR-PF | CR-PF | |
|---|---|---|---|---|
| Average hospital stays (d) | ||||
| Normality test | 0.009 | 0.024 | 0.004 | 0.06 |
|
| 0.000a | 0.000b | ||
| Mean (d) | 22.25 | 39.08 | 23.33 | 46.42 |
| Standard deviation | 15.80 | |||
|
| ||||
| Average hospital charges | ||||
| Normality test | 0.223 | 0.617 | 0.279 | 0.915 |
|
| 0.000a | 0.001b | ||
| Mean (yuan) | 56323.47 | 83347.93 | 61339.84 | 81448.18 |
| Standard deviation | 24360.81 | 32007.30 | 28166.70 | 31699.74 |
Missing values: data missing for 8 patients in hospital charges. a P value of nonparametric test between PF and NOPF groups; b P value of t test between NOCR-PF and CR-PF groups.
(a) Patient-related factors for PF
| Variants | PF | NOPF | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | ORadj (95% CI) |
| ORadj (95% CI) |
| |
| Smoking | 0.499 | |||||
| Yes | 34 (27.0) | 68 (23.8) | 1 | |||
| No | 92 (73.0) | 218 (76.2) | 0.847 (0.524–1.370) | |||
| Heavy smoking (cigarettes/day) | 0.17 | |||||
| ≥20 | 24 (19.0) | 39 (13.6) | 1 | |||
| <20 | 102 (81.0) | 247 (86.4) | 0.675 (0.385–1.184) | |||
| Excessive drinking | 0.029 | 0.003 | ||||
| Yes | 35 (27.8) | 53 (18.5) | 1 | 1 | ||
| No | 91 (72.2) | 233 (81.5) | 0.577 (0.352–0.947) | 0.390 (0.210–0.724) | ||
| Cholangitis | 0.06 | |||||
| Yes | 21 (16.7) | 29 (10.1) | 1 | |||
| No | 105 (83.3) | 257 (89.9) | 0.577 (0.303–1.024) | |||
| Cholecystitis | 0.054 | |||||
| Yes | 105 (83.3) | 213 (74.5) | 1 | |||
| No | 21 (16.7) | 73 (25.5) | 0.588 (0.342–1.010) | |||
| Jaundice | 0.671 | |||||
| Yes | 87 (69.0) | 202 (70.6) | 1 | |||
| No | 39 (31.0) | 84 (29.4) | 1.104 (0.698–1.747) | |||
| Coronary heart disease | 0.029 | 0.018 | ||||
| Yes | 16 (12.7) | 16 (5.6) | 1 | 1 | ||
| No | 110 (87.3) | 270 (94.4) | 0.441 (0.211–0.919) | 0.324 (0.127–0.828) | ||
| Hypertension | 0.353 | |||||
| Yes | 17 (13.6) | 26 (9.1) | 1 | |||
| No | 108 (86.4) | 259 (90.9) | 0.728 (0.373–1.422) | |||
| Diabetes mellitus | 0.624 | |||||
| Yes | 14 (11.2) | 27 (9.5) | 1 | |||
| No | 111 (88.8) | 257 (90.5) | 0.842 (0.424–1.674) | |||
| Preoperative serum total bilirubin ( | 0.83 | |||||
| ≤17.1 | 28 (22.2) | 63 (22.0) | 1 | |||
| >17.1 | 98 (77.8) | 223 (78.0) | 0.946 (0.568–1.573) | |||
| Preoperative hemoglobin (g/L) | 0.964 | |||||
| <90 | 3 (2.4) | 7 (2.4) | 1 | |||
| ≥90 | 123 (97.6) | 279 (97.6) | 1.032 (0.261–4.087) | |||
| Preoperative serum albumin (g/L) | 0.006 | |||||
| <30 | 10 (7.9) | 6 (2.1) | 1 | 1 | 0.007 | |
| ≥30 | 116 (92.1) | 280 (97.9) | 0.235 (0.083–0.666) | 0.182 (0.053–0.626) | ||
| Postoperative serum albumin (g/L) | 0.095 | |||||
| <30 | 51 (40.5) | 93 (32.5) | 1 | |||
| ≥30 | 75 (59.5) | 193 (67.5) | 0.689 (0.445–1.067) | |||
| Primary site of disease | 0.674 | |||||
| Caput pancreatis | 59 (46.8) | 129 (45.1) | 1 | |||
| Duodenum | 34 (27.0) | 89 (31.1) | 0.815 (0.492–1.349) | |||
| Biliary ducts | 33 (26.2) | 68 (23.8) | 1.019 (0.605–1.717) | |||
| Pathologic diagnosis | 0.371 | |||||
| Caput pancreatis cancer | 48 (38.1) | 91 (31.8) | 1 | |||
| Duodenal cancer | 21 (16.7) | 60 (21.0) | 0.642 (0.348–1.184) | |||
| Cholangiocarcinoma | 30 (23.8) | 62 (21.7) | 0.906 (0.516–1.590) | |||
| Pancreatitis | 4 (3.2) | 21 (7.3) | 0.416 (0.134–1.294) | |||
| Carcinoma of ampulla | 6 (4.8) | 20 (7.0) | 0.588 (0.220–1.570) | |||
| Others | 17 (13.5) | 32 (11.2) | 1.141 (0.568–2.295) | |||
| Texture of the remnant pancreas | 0.016 | 0.037 | ||||
| Hard | 20 (15.9) | 77 (26.9) | 1 | 1 | ||
| Soft | 106 (84.1) | 209 (73.1) | 1.964 (1.136–3.394) | 1.955 (1.042–3.669) | ||
| Diameter of pancreatic duct (mm) | 0.496 | |||||
| <3 | 68 (54.0) | 142 (49.7) | 1 | |||
| ≥3 | 58 (46.0) | 144 (50.3) | 0.863 (0.566–1.318) | |||
(b) Operative- and therapeutic-related factors for PF
| Variants | PF | NOPF | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | ORadj (95% CI) |
| ORadj (95% CI) |
| |
| Preoperative biliary drainage treatment | ||||||
| Yes | 13 (10.3) | 25 (8.7) | 1 | 0.535 | ||
| No | 113 (89.7) | 261 (91.3) | 0.798 (0.392–1.625) | |||
| Operative time (min) | — | |||||
| <295 | 19 (15.1) | 67 (22.9) | 1 | 0.161 | — | |
| ≥295 | 107 (84.9) | 226 (77.1) | 0.669 (0.380–1.177) | — | ||
| Intraoperative blood loss (mL) | 0.003 | — | — | |||
| <300 | 35 (27.8) | 121 (42.3) | 1 | — | — | |
| 300–600 | 30 (23.8) | 81 (28.3) | 1.194 (0.675–2.113) | — | — | |
| 600–900 | 28 (22.2) | 45 (15.7) | 2.089 (1.139–3.830) | — | — | |
| ≥900 | 33 (26.2) | 39 (13.6) | 2.738 (1.498–5.005) | — | — | |
| Intraoperative blood transfusion (mL) | 0.000 | 0.000 | ||||
| <300 | 41 (32.5) | 136 (47.6) | 1 | 1 | ||
| 300–600 | 23 (18.3) | 67 (23.4) | 1.112 (0.616–2.008) | 1.128 (0.556–2.290) | 0.738 | |
| 600–900 | 31 (24.6) | 57 (19.9) | 1.754 (1.000–3.078) | 2.574 (1.318–5.025) | 0.006 | |
| ≥900 | 31 (24.6) | 26 (9.1) | 3.711 (1.969–6.995) | 5.115 (2.364–11.069) | 0.000 | |
| Pancreatic duct stent drainage | 0.000 | 0.394 | ||||
| No stent | 40 (31.7) | 49 (17.1) | 1 | 1 | 0.570 | |
| Internal drainage | 77 (61.1) | 174 (60.8) | 0.518 (0.313–0.856) | 0.819 (0.412–1.629) | 0.178 | |
| External drainage | 9 (7.1) | 63 (22.0) | 0.162 (0.071–0.370) | 0.476 (0.161–1.403) | 0.624 | |
| Excision method | 0.016 | 0.624 | ||||
| Without PP | 108 (85.7) | 266 (93.0) | 1 | 1 | ||
| With PP | 18 (14.3) | 20 (7.0) | 2.300 (1.165–4.543) | 1.240 (0.524–2.932) | ||
| Methods of anastomosis | 0.005 | 0.026 | ||||
| Binding anastomosis | 3 (2.4) | 22 (7.7) | 1 | 1 | ||
| End-side invagination anastomosis | 6 (4.8) | 38 (13.3) | 1.110 (0.251–4.911) | 2.428 (0.439–13.432) | ||
| End-end invagination anastomosis | 106 (84.1) | 194 (67.8) | 3.922 (1.143–13.456) | 5.510 (1.391–21.821) | ||
| Duct-mucosa anastomosis | 11 (8.7) | 32 (11.2) | 2.396 (0.595–9.642) | 7.918 (1.619–38.722) | ||
| Laparoscopic operation | 0.002 | 0.034 | ||||
| Yes | 10 (7.9) | 3 (1.0) | 1 | 1 | ||
| No | 116 (92.1) | 283 (99.0) | 0.128 (0.034–0.477) | 0.188 (0.040–0.883) | ||
| Early jejunal nutrition | 0.065 | |||||
| Yes | 25 (19.8) | 81 (28.3) | 1 | |||
| No | 101 (80.2) | 205 (71.7) | 1.617 (0.970–2.694) | |||
| Use of somatostatin after PD | 0.059 | |||||
| Yes | 84 (66.7) | 161 (56.3) | 1 | |||
| No | 42 (33.3) | 125 (43.7) | 0.655 (0.422–1.017) | |||
| Professional group | 0.000 | 0.000 | ||||
| Yes | 38 (30.2) | 190 (66.4) | 1 | 1 | ||
| No | 88 (69.8) | 96 (33.6) | 4.718 (2.985–7.457) | 3.925 (2.250–6.847) | ||
—: the multivariate analysis of intraoperative blood loss was not performed in this study because of its corresponding relationship with intraoperative blood transfusion. Missing values: 3 diabetes mellitus patients and 2 hypertension patients were missing. OR: odds ratio; CI: confidence interval; ORadj: adjusted ORs presented with 95% CI.
(a) Patient-related factors for CR-PF
| Variants | CR-PF | NOCR-PF | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | ORadj (95% CI) |
| ORadj (95% CI) |
| |
| Smoking | 0.84 | |||||
| Yes | 19 (25.7) | 83 (24.6) | 1 | |||
| No | 55 (74.3) | 255 (75.4) | 0.942 (0.529–1.678) | |||
| Heavy smoking (cigarettes/day) | 0.191 | |||||
| ≥20 | 15 (20.3) | 48 (14.2) | 1 | |||
| <20 | 59 (79.3) | 290 (85.8) | 0.651 (0.342–1.239) | |||
| Excessive drinking | 0.493 | |||||
| Yes | 18 (24.3) | 70 (20.7) | 1 | |||
| No | 56 (75.7) | 268 (79.3) | 0.813 (0.449–1.470) | |||
| Cholangitis | 0.002 | |||||
| Yes | 17 (23.0) | 33 (9.8) | 1 | |||
| No | 57 (77.0) | 305 (90.2) | 0.363 (0.189–0.695) | |||
| Cholecystitis | 0.075 | 0.004 | ||||
| Yes | 63 (85.1) | 255 (75.4) | 1 | 1 | ||
| No | 11 (14.9) | 83 (24.6) | 0.536 (0.270–1.066) | 0.321 (0.150–0.690) | ||
| Jaundice | 0.054 | |||||
| Yes | 45 (60.8) | 244 (72.2) | 1 | |||
| No | 29 (39.2) | 94 (27.8) | 1.673 (0.991–2.825) | |||
| Coronary heart disease | 0.284 | |||||
| Yes | 8 (10.8) | 24 (7.1) | 1 | |||
| No | 66 (89.2) | 314 (92.9) | 0.631 (0.271–1.465) | |||
| Hypertension | 0.572 | |||||
| Yes | 9 (12.3) | 34 (10.1) | 1 | |||
| No | 64 (87.7) | 303 (89.9) | 0.798 (0.365–1.745) | |||
| Diabetes mellitus | 0.163 | |||||
| Yes | 4 (5.5) | 37 (11.0) | 1 | |||
| No | 69 (94.5) | 299 (89.0) | 2.135 (0.736–6.188) | |||
| Preoperative serum total bilirubin ( | 0.412 | |||||
| ≤17.1 | 19 (25.7) | 72 (21.3) | 1 | |||
| >17.1 | 55 (74.3) | 266 (78.7) | 0.784 (0.437–1.404) | |||
| Preoperative hemoglobin (g/L) | 0.324 | |||||
| <90 | 3 (4.1) | 7 (2.1) | 1 | |||
| ≥90 | 71 (95.9) | 331 (97.9) | 0.501 (0.126–1.983) | |||
| Preoperative serum albumin (g/L) | 0 | 0.000 | ||||
| <30 | 9 (12.2) | 7 (2.1) | 1 | 1 | ||
| ≥30 | 65 (87.8) | 331 (97.9) | 0.153 (0.055–0.425) | 0.107 (0.031–0.363) | ||
| Postoperative serum albumin (g/L) | 0.971 | |||||
| <30 | 26 (35.1) | 118 (34.9) | 1 | |||
| ≥30 | 48 (64.9) | 220 (65.1) | 0.990 (0.585–1.677) | |||
| Primary site of disease | 0.935 | |||||
| Caput pancreatis | 34 (45.9) | 154 (45.6) | 1 | |||
| Duodenum | 23 (31.1) | 100 (29.6) | 1.042 (0.580–1.872) | |||
| Biliary ducts | 17 (23.0) | 84 (24.9) | 0.917 (0.483–1.738) | |||
| Pathologic diagnosis | 0.322 | |||||
| Caput pancreatis cancer | 28 (37.8) | 111 (32.8) | 1 | |||
| Duodenal cancer | 13 (17.6) | 68 (20.1) | 0.758 (0.368–1.563) | |||
| Cholangiocarcinoma | 15 (20.3) | 77 (22.8) | 0.772 (0.387–1.542) | |||
| Pancreatitis | 1 (1.4) | 24 (7.1) | 0.165 (0.021–1.274) | |||
| Carcinoma of ampulla | 4 (5.4) | 22 (6.5) | 0.721 (0.230–2.261) | |||
| Others | 13 (17.6) | 36 (10.7) | 1.432 (0.671–3.054) | |||
| Texture of the remnant pancreas | 0.013 | 0.044 | ||||
| Hard | 9 (12.2) | 88 (26.0) | 1 | 1 | ||
| Soft | 65 (87.8) | 250 (74.0) | 2.542 (1.215–5.319) | 2.316 (1.205–5.234) | ||
| Diameter of pancreatic duct (mm) | 0.400 | |||||
| <3 | 41 (55.4) | 169 (50.0) | 1 | |||
| ≥3 | 33 (44.6) | 169 (50.0) | 0.805 (0.485–1.334) | |||
(b) Operative- and therapeutic-related factors for CR-PF
| Variants | CR-PF | NOCR-PF | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | ORadj (95% CI) |
| ORadj (95% CI) |
| |
| Preoperative biliary drainage treatment | 0.068 | |||||
| Yes | 11 (14.9) | 27 (8.0) | 1 | |||
| No | 63 (85.1) | 311 (92.0) | 0.497 (0.235–1.054) | |||
| Operative time (min) | 1.081 | |||||
| <295 | 11 (14.9) | 68 (20.1) | 1 | |||
| ≥295 | 63 (85.1) | 270 (79.9) | 0.693 (0.347–1.387) | |||
| Intraoperative blood loss (mL) | 0.004 | — | — | |||
| <300 | 20 (27.0) | 136 (40.2) | 1 | — | — | |
| 300–600 | 14 (18.9) | 97 (28.7) | 0.981 (0.473–2.039) | — | — | |
| 600–900 | 20 (27.0) | 53 (15.7) | 2.566 (1.279–5.148) | — | — | |
| ≥900 | 20 (27.0) | 52 (15.4) | 2.615 (1.302–5.253) | — | — | |
| Intraoperative blood transfusion (mL) | 0.002 | 0.001 | ||||
| <300 | 19 (25.7) | 158 (46.7) | 1 | 1 | ||
| 300–600 | 18 (24.3) | 72 (21.3) | 2.079 (1.030–4.196) | 2.311 (1.049–5.092) | 0.038 | |
| 600–900 | 18 (24.3) | 70 (20.7) | 2.138 (1.058–4.321) | 2.657 (1.207–5.851) | 0.015 | |
| ≥900 | 19 (25.7) | 38 (11.2) | 4.158 (2.008–8.609) | 5.337 (2.301–12.376) | 0.000 | |
| Pancreatic duct stent drainage | 0.007 | 0.542 | ||||
| No stent | 24 (32.4) | 65 (19.2) | 1 | 1 | ||
| Internal drainage | 45 (60.8) | 206 (60.9) | 0.592 (0.335–1.045) | 0.692 (0.359–1.334) | 0.272 | |
| External drainage | 5 (6.8) | 67 (19.8) | 0.202 (0.073–0.562) | 0.814 (0.248–2.671) | 0.375 | |
| Excision method | 0.068 | |||||
| Without PP | 63 (85.1) | 311 (92.0) | 1 | |||
| With PP | 11 (14.9) | 27 (8.0) | 2.011 (0.949–4.264) | |||
| Methods of anastomosis | 0.069 | |||||
| Binding anastomosis | 2 (2.7) | 23 (6.8) | 1 | |||
| End-side invagination anastomosis | 3 (4.1) | 41 (12.1) | 0.841 (0.131–5.409) | |||
| End-end invagination anastomosis | 63 (85.1) | 237 (70.1) | 3.057 (0.702–13.314) | |||
| Duct-mucosa anastomosis | 6 (8.1) | 37 (10.9) | 1.865 (0.347–10.034) | |||
| Laparoscopic operation | 0.231 | |||||
| Yes | 4 (5.4) | 9 (2.7) | 1 | |||
| No | 70 (94.6) | 329 (97.3) | 0.479 (0.143–1.599) | |||
| Early jejunal nutrition | 0.238 | |||||
| Yes | 15 (20.3) | 91 (26.9) | 1 | |||
| No | 59 (79.7) | 247 (73.1) | 1.449 (0.783–2.682) | |||
| Use of somatostatin after PD | 0.069 | |||||
| Yes | 51 (68.9) | 194 (57.4) | 1 | |||
| No | 23 (31.1) | 144 (42.6) | 0.608 (0.355–1.040) | |||
| Professional group | 0.000 | 0.000 | ||||
| Yes | 16 (21.6) | 212 (62.7) | 1 | 1 | ||
| No | 58 (78.4) | 126 (37.3) | 6.099 (3.362–11.066) | 5.674 (2.867–11.230) | ||
—: the multivariate analysis of intraoperative blood loss was not performed in this study because of its corresponding relationship with intraoperative blood transfusion. Missing values: 3 diabetes mellitus patients and 2 hypertension patients were missing. OR: odds ratio; CI: confidence interval; ORadj: adjusted ORs presented with 95% CI.